...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Cytokine >Different effect of unfractionated heparin and enoxaparin on circulating proangiogenic factors during hemodialysis: A cross-over study.
【24h】

Different effect of unfractionated heparin and enoxaparin on circulating proangiogenic factors during hemodialysis: A cross-over study.

机译：普通肝素和依诺肝素对血液透析过程中循环促血管生成因子的不同作用：一项交叉研究。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background. We aimed to compare the effect of unfractionated heparin (UFH) and enoxaparin used as anticoagulants during hemodialysis (HD) on circulating levels of heparin-binding, endothelial-derived, proangiogenic factors-vascular endothelial (VEGF(165)) and basic fibroblast (bFGF) growth factor. Methods. We enrolled 22 chronic HD patients, who were randomly assigned to either enoxaparin (n=11) or UFH (n=11) anticoagulation, and followed prospectively for 12 weeks before crossing over to the alternate therapy for further 12 weeks. The cytokines were measured by immunoassay at the start, at 10 and 180min of HD. Results. The baseline VEGF(165) and bFGF levels were comparable during enoxaparin and UFH treatment. VEGF(165) significantly decreased during both enoxaparin (chi(2) ANOVA=33.0, P<10(-6)) and UFH (chi(2) ANOVA=27.2, P<10(-6)) anticoagulated HD, while over-HD bFGF remained stable regardless of the type of heparin. The switch from enoxaparin to UFH treatment was connected with 34% VEGF(165) decrease after 180min of HD and had no impact on bFGF. During UFH-anticoagulated HD 75% VEGF(165) decrease after 10min was negatively associated with heparin dosage and was more profound in patients with ischemic heart disease. Conclusion. The traditional UFH regimen, in contrast to enoxaparin treatment, is connected with dose-depended VEGF(165) decrease during HD procedure. The biological and possible clinical relevance of this observation requires further investigations.
机译：背景。我们的目的是比较血液透析（HD）过程中普通肝素（UFH）和依诺肝素作为抗凝剂对肝素结合，内皮源性，促血管生成因子-血管内皮（VEGF（165））和碱性成纤维细胞（bFGF）循环水平的影响）增长因子。方法。我们招募了22名慢性HD患者，他们被随机分配为依诺肝素（n = 11）或UFH（n = 11）抗凝治疗，并进行前瞻性随访12周，然后再进行替代治疗12周。在HD开始时10分钟和180分钟通过免疫测定法测量细胞因子。结果。依诺肝素和UFH治疗期间的基线VEGF（165）和bFGF水平相当。依诺肝素（chi（2）ANOVA = 33.0，P <10（-6））和UFH（chi（2）ANOVA = 27.2，P <10（-6））抗凝HD均显着降低VEGF（165） -HD bFGF保持稳定，无论肝素类型如何。 HD 180分钟后，从依诺肝素改用UFH与VEGF减少34％（165）有关，且对bFGF无影响。在UFH抗凝高清过程中，在10分钟后75％VEGF（165）的降低与肝素剂量呈负相关，在缺血性心脏病患者中更为明显。结论。与依诺肝素治疗相反，传统的UFH方案与HD手术期间剂量依赖性VEGF（165）降低有关。这种观察的生物学和可能的临床意义需要进一步的研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号